Safety and Efficacy of Fingolimod and Ocrelizumab in Pediatric Patients With Multiple Sclerosis.

Background: Fingolimod and ocrelizumab are approved treatments for adults with multiple sclerosis (MS); however, only fingolimod is approved by the Food and Drug Administration for the treatment of pediatric MS. Currently, there are limited data for the safety and efficacy of ocrelizumab use in children.

Methods: This retrospective cohort study included patients with relapsing-remitting MS who started either ocrelizumab or fingolimod before age 18 years.

Splicing accuracy varies across human introns, tissues, age and disease.

Alternative splicing impacts most multi-exonic human genes. Inaccuracies during this process may have an important role in ageing and disease. Here, we investigate splicing accuracy using RNA-sequencing data from >14k control samples and 40 human body sites, focusing on split reads partially mapping to known transcripts in annotation.

Reflections on deep academic-practitioner partnering for generative societal impact.

While academics increasingly point to the value of engaged scholarship, we describe a more extreme form which we label as "deep partnering"-a long-term, holistic, and dynamic collaboration between academics and practitioners to achieve shared goals. Deep partnering involves interdependent and evolving interactions between academics and practitioners over an extended time period. While such relationships enable generative impact on important issues, these relationships remain challenging as academics spend time in the practitioners' complex worlds, surfacing paradoxes due to the partners' conflicting roles, time horizons, and goals, as well as uncertainty in the partnership's evolution.